ReviewJournal of physiology and biochemistry2026
Programmed cell death protein 4 (PDCD4): a pleiotropic regulator in cardiovascular diseases.
Review in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, yet the molecular mechanisms are incompletely understood. Programmed cell death protein 4 (PDCD4), originally identified as a tumor suppressor and inhibitor of eIF4A-dependent translation, has emerged as a cardiovascular stress-response node. Accumulating evidence indicates that PDCD4 expression is controlled at epigenetic, transcriptional, post-transcriptional, translational, and post-translational levels. Across atherosclerosis, myocardial infarction, myocardial ischemia/reperfusion injury, cardiomyopathy, atrial fibrillation, pulmonary hypertension, and aneurysm, dysregulated PDCD4 links noncoding-RNA signaling and translational control to inflammation, apoptosis, autophagy, oxidative and mitochondrial injury, and phenotypic remodeling. Most experimental studies associate PDCD4 suppression with cardiovascular protection. However, the biological effects of PDCD4 appear to vary according to cell lineage, disease stage, subcellular localization, post-translational state, and tissue microenvironment. This review summarizes the molecular architecture and regulatory networks of PDCD4, integrates disease-specific evidence and cardiovascular functions, and critically discusses the opportunities and challenges of targeting PDCD4 for cardiovascular therapy.
Indexed as
Identifiers
42828639What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.